Cairo – Mubasher: The board of directors of Glaxo SmithKline (GSK Egypt) agreed to allow Hikma Pharmaceuticals Plc to conduct due diligence on the company, according to a bourse disclosure on Wednesday.
On Tuesday, the company said that its majority shareholder Glaxo Group Limited signed a non-binding term sheet with Hikma Pharmaceuticals Plc for the potential sale of its entire stake of 91.2% in GSK Egypt.
During the first nine months of 2020, GSK Egypt reported net profits of EGP 101.41 million, up from EGP 67.03 million in the corresponding period a year earlier.
